David Munn

Summary

Affiliation: Medical College of Georgia
Country: USA

Publications

  1. pmc Lineage-specific transcription factors in unexpected places
    David H Munn
    Department of Pediatrics, Medical College of Georgia, Augusta, GA, USA
    Eur J Immunol 40:315-7. 2010
  2. ncbi Indoleamine 2,3-dioxygenase, tumor-induced tolerance and counter-regulation
    David H Munn
    Immunotherapy Center and Department of Pediatrics, Medical College of Georgia, Augusta, Georgia 30912, USA
    Curr Opin Immunol 18:220-5. 2006
  3. ncbi GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase
    David H Munn
    Department of Pediatrics, Medical College of Georgia, Augusta, GA 30912, USA
    Immunity 22:633-42. 2005
  4. pmc Indoleamine 2,3-dioxygenase and tumor-induced tolerance
    David H Munn
    Immunotherapy Program, Department of Pediatrics, MCG Cancer Center, Medical College of Georgia, Augusta, GA 30912, USA
    J Clin Invest 117:1147-54. 2007
  5. pmc Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes
    David H Munn
    Department of Pediatrics, Institute for Molecular Medicine and Genetics, Medical College of Georgia, Augusta, Georgia 30912, USA
    J Clin Invest 114:280-90. 2004
  6. ncbi Ligation of B7-1/B7-2 by human CD4+ T cells triggers indoleamine 2,3-dioxygenase activity in dendritic cells
    David H Munn
    Institute of Molecular Medicine and Genetics and Departments of Pediatrics, Medical College of Georgia, Augusta, GA 30912, USA
    J Immunol 172:4100-10. 2004
  7. ncbi IDO and tolerance to tumors
    David H Munn
    Department of Pediatrics, Institute of Molecular Medicine and Genetics, Medical College of Georgia, Augusta, GA 30912, USA
    Trends Mol Med 10:15-8. 2004
  8. ncbi Macrophages and the regulation of self-reactive T cells
    David H Munn
    Institute of Molecular Medicine and Genetics, Medical College of Georgia, Augusta, GA 30912, USA
    Curr Pharm Des 9:257-64. 2003
  9. pmc Inhibition of T cell proliferation by macrophage tryptophan catabolism
    D H Munn
    Institute of Molecular Medicine and Genetics, Medical College of Georgia, Augusta, Georgia 30912, USA
    J Exp Med 189:1363-72. 1999
  10. ncbi Tolerogenic antigen-presenting cells
    David H Munn
    Medical College of Georgia, Room IMMAG, Mail Stop CA 2010, Augusta, GA 30912, USA
    Ann N Y Acad Sci 961:343-5. 2002

Research Grants

  1. IDO-expressing plasmacytoid dendritic cells and tumors
    David Munn; Fiscal Year: 2007
  2. IDO-expressing immunoregulatory dendritic cells
    David Munn; Fiscal Year: 2007
  3. Role of IDO malignancy
    David Munn; Fiscal Year: 2007
  4. IDO-expressing plasmacytoid dendritic cells and tumors
    David Munn; Fiscal Year: 2009
  5. IDO-expressing immunoregulatory dendritic cells
    David Munn; Fiscal Year: 2009
  6. IDO-mediated immune regulation in established tumors
    David H Munn; Fiscal Year: 2010
  7. IDO-expressing immunoregulatory dendritic cells
    David H Munn; Fiscal Year: 2010
  8. Role of IDO in Malignancy
    David Munn; Fiscal Year: 2006
  9. MACROPHAGE MEDIATED IMMUNOREGULATION VIA TRYPTOPHAN
    David Munn; Fiscal Year: 2002
  10. Role of IDO malignancy
    David H Munn; Fiscal Year: 2010

Detail Information

Publications56

  1. pmc Lineage-specific transcription factors in unexpected places
    David H Munn
    Department of Pediatrics, Medical College of Georgia, Augusta, GA, USA
    Eur J Immunol 40:315-7. 2010
    ..Thus, a transcription factor not native to DC nevertheless conferred elements of a regulatory phenotype following ectopic expression...
  2. ncbi Indoleamine 2,3-dioxygenase, tumor-induced tolerance and counter-regulation
    David H Munn
    Immunotherapy Center and Department of Pediatrics, Medical College of Georgia, Augusta, Georgia 30912, USA
    Curr Opin Immunol 18:220-5. 2006
    ..Strategies to inhibit the IDO pathway may thus assist in breaking tolerance to tumors, and might enhance the efficacy of other immunotherapy strategies by removing unwanted counter-regulation...
  3. ncbi GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase
    David H Munn
    Department of Pediatrics, Medical College of Georgia, Augusta, GA 30912, USA
    Immunity 22:633-42. 2005
    ..We hypothesize that GCN2 acts as a molecular sensor in T cells, allowing them to detect and respond to conditions created by IDO...
  4. pmc Indoleamine 2,3-dioxygenase and tumor-induced tolerance
    David H Munn
    Immunotherapy Program, Department of Pediatrics, MCG Cancer Center, Medical College of Georgia, Augusta, GA 30912, USA
    J Clin Invest 117:1147-54. 2007
    ..It can also function as an antagonist to other activators of antitumor immunity. Therefore, strategies to block IDO might enhance the effectiveness of tumor immunotherapy...
  5. pmc Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes
    David H Munn
    Department of Pediatrics, Institute for Molecular Medicine and Genetics, Medical College of Georgia, Augusta, Georgia 30912, USA
    J Clin Invest 114:280-90. 2004
    ..We hypothesize that IDO-mediated suppression by pDCs in TDLNs creates a local microenvironment that is potently suppressive of host antitumor T cell responses...
  6. ncbi Ligation of B7-1/B7-2 by human CD4+ T cells triggers indoleamine 2,3-dioxygenase activity in dendritic cells
    David H Munn
    Institute of Molecular Medicine and Genetics and Departments of Pediatrics, Medical College of Georgia, Augusta, GA 30912, USA
    J Immunol 172:4100-10. 2004
    ..We hypothesize that IDO activation via engagement of B7-1/B7-2 molecules on DCs, specifically, engagement by CTLA4 expressed on regulatory CD4(+) T cells, may function as a physiologic regulator of T cell responses in vivo...
  7. ncbi IDO and tolerance to tumors
    David H Munn
    Department of Pediatrics, Institute of Molecular Medicine and Genetics, Medical College of Georgia, Augusta, GA 30912, USA
    Trends Mol Med 10:15-8. 2004
  8. ncbi Macrophages and the regulation of self-reactive T cells
    David H Munn
    Institute of Molecular Medicine and Genetics, Medical College of Georgia, Augusta, GA 30912, USA
    Curr Pharm Des 9:257-64. 2003
    ..This review examines the array of immunosuppressive mechanisms which may help macrophages suppress unwanted T cell responses, and considers the consequences of a breakdown in these negative-regulatory systems in autoimmunity...
  9. pmc Inhibition of T cell proliferation by macrophage tryptophan catabolism
    D H Munn
    Institute of Molecular Medicine and Genetics, Medical College of Georgia, Augusta, Georgia 30912, USA
    J Exp Med 189:1363-72. 1999
    ..We speculate that expression of IDO by certain antigen presenting cells in vivo allows them to suppress unwanted T cell responses...
  10. ncbi Tolerogenic antigen-presenting cells
    David H Munn
    Medical College of Georgia, Room IMMAG, Mail Stop CA 2010, Augusta, GA 30912, USA
    Ann N Y Acad Sci 961:343-5. 2002
  11. ncbi Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase
    David H Munn
    Institute of Molecular Medicine and Genetics, Medical College of Georgia, Augusta, GA 30912, USA
    Science 297:1867-70. 2002
    ..IDO+ DCs could also be readily detected in vivo, which suggests that these cells may represent a regulatory subset of APCs in humans...
  12. ncbi Tryptophan catabolism and T cell responses
    Andrew L Mellor
    Program in Molecular Immunology, Institute of Molecular Medicine and Genetics, Department of Medicine, Medical College of Georgia, Augusta, GA 30912, USA
    Adv Exp Med Biol 527:27-35. 2003
    ....
  13. ncbi A minor population of splenic dendritic cells expressing CD19 mediates IDO-dependent T cell suppression via type I IFN signaling following B7 ligation
    Babak Baban
    Immunotherapy Center, Medical College of Georgia, 1120, 15th Street, Augusta, GA 30912, USA
    Int Immunol 17:909-19. 2005
    ..Thus, CD19+ DCs may be a target for regulatory T cells expressing surface CTLA4, and may suppress T cell responses via induction of IDO...
  14. pmc Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase
    Madhav D Sharma
    Department of Pediatrics, School of Medicine, Medical College of Georgia, Augusta, Georgia 30912, USA
    J Clin Invest 117:2570-82. 2007
    ..We hypothesize that IDO+ pDCs create a profoundly suppressive microenvironment within tumor-draining LNs via constitutive activation of Tregs...
  15. pmc IDO activates regulatory T cells and blocks their conversion into Th17-like T cells
    Babak Baban
    Immunotherapy and Cancer Centers, Department of Pathology, Medical College of Georgia, Augusta, GA 30912, USA
    J Immunol 183:2475-83. 2009
    ..These findings support the hypothesis that IDO dominantly controls the functional status of Tregs in response to inflammatory stimuli in physiological settings...
  16. pmc Indoleamine 2,3-dioxygenase controls conversion of Foxp3+ Tregs to TH17-like cells in tumor-draining lymph nodes
    Madhav D Sharma
    Department of Pediatrics, Medical College of Georgia, Augusta, GA 30912, USA
    Blood 113:6102-11. 2009
    ..Thus, Tregs in TDLNs can be actively reprogrammed in situ into T-helper cells, without the need for physical depletion, and IDO serves as a key regulator of this critical conversion...
  17. pmc Tryptophan deprivation sensitizes activated T cells to apoptosis prior to cell division
    Geon Kook Lee
    Program in Molecular Immunology, Institute of Molecular Medicine and Genetics, Medical College of Georgia, Augusta, GA 30912, USA
    Immunology 107:452-60. 2002
    ....
  18. pmc Role of CD28 in fatal autoimmune disorder in scurfy mice
    Nagendra Singh
    Immunotherapy Center, Medical College of Georgia, Augusta, USA
    Blood 110:1199-206. 2007
    ..These data support the hypothesis that CD28-B7 interactions play a critical role in the etiology of lethal autoimmune disease in scurfy mice by stimulating the differentiation of antigen-activated naive T cells into effector T cells...
  19. ncbi Decreased protein nitration in macrophages that overexpress indoleamine 2, 3-dioxygenase
    Derin B Keskin
    Institute of Molecular Medicine and Genetics, Medical College of Georgia, Augusta, GA, 30912, USA
    Cell Mol Biol Lett 12:82-102. 2007
    ..Our results are consistent with the concept that, besides degrading tryptophan, IDO activity may protect cells from oxidative damage...
  20. ncbi A high-affinity, tryptophan-selective amino acid transport system in human macrophages
    Robert L Seymour
    Immunotherapy Center, CN 4141, Medical College of Georgia, Augusta, GA 30912, USA
    J Leukoc Biol 80:1320-7. 2006
    ....
  21. pmc Chronic inflammation that facilitates tumor progression creates local immune suppression by inducing indoleamine 2,3 dioxygenase
    Alexander J Muller
    Immunotherapy and Cancer Centers, Flow Cytometry Core Facility, and Departments of Pediatrics and Medicine, Medical College of Georgia, Augusta, GA 30912, USA
    Proc Natl Acad Sci U S A 105:17073-8. 2008
    ..Thus, IDO is a key immunosuppressive factor that facilitates tumor progression in this setting of chronic inflammation driven by repeated topical PMA exposure...
  22. ncbi Cell-autonomous control of interferon type I expression by indoleamine 2,3-dioxygenase in regulatory CD19+ dendritic cells
    Anna K Manlapat
    Immunotherapy and Cancer Centers, Department of Medicine, Medical College of Georgia, Augusta, GA 30912, USA
    Eur J Immunol 37:1064-71. 2007
    ..In the case of B7 ligation, IDO activates cell-autonomous signals essential for IFN-alpha production, most likely by activating the GCN2-kinase-dependent stress response...
  23. ncbi Tryptophan catabolism and regulation of adaptive immunity
    Andrew L Mellor
    Department of Medicine, Medical College of Georgia, Augusta GA 30912, USA
    J Immunol 170:5809-13. 2003
  24. pmc Blockade of programmed death-1 pathway rescues the effector function of tumor-infiltrating T cells and enhances the antitumor efficacy of lentivector immunization
    Qifeng Zhou
    Immunology Immunotherapy Program, Medical College of Georgia Cancer Center, Medical College of Georgia, Augusta, GA 30912, USA
    J Immunol 185:5082-92. 2010
    ....
  25. pmc Recombinant lentivector as a genetic immunization vehicle for antitumor immunity
    Yukai He
    Medical College of Georgia, Immunology Immunotherapy Program, MCG Cancer Center, CN 4150, 1120 15th Street, Augusta, GA 30912, USA
    Expert Rev Vaccines 6:913-24. 2007
    ....
  26. pmc Obesity related methylation changes in DNA of peripheral blood leukocytes
    Xiaoling Wang
    Georgia Prevention Institute, Department of Pediatrics, Medical College of Georgia, Augusta, GA, USA
    BMC Med 8:87. 2010
    ..Because of emerging evidence that immune responses are epigenetically regulated, we hypothesized that DNA methylation changes are involved in obesity induced immune dysfunction and aimed to identify these changes...
  27. ncbi IDO expression by dendritic cells: tolerance and tryptophan catabolism
    Andrew L Mellor
    Program in Molecular Immunology, Institute of Molecular Medicine and Genetics, Department of Medicine, Medical College of Georgia, Augusta, Georgia 30912, USA
    Nat Rev Immunol 4:762-74. 2004
    ..In this review, we summarize key recent developments and propose a unifying model for the role of IDO in tolerance induction...
  28. ncbi The tumor-draining lymph node as an immune-privileged site
    David H Munn
    Immunotherapy Center, Department of Pediatrics, Medical College of Georgia, Augusta, GA 30912, USA
    Immunol Rev 213:146-58. 2006
    ..These mechanisms will need to be interrupted in order for clinical anti-tumor immunotherapy to be successful...
  29. ncbi Cells expressing indoleamine 2,3-dioxygenase inhibit T cell responses
    Andrew L Mellor
    Program in Molecular Immunology, Institute of Molecular Medicine and Genetics, Department of Medicine, Medical College of Georgia, Augusta, GA 30912, USA
    J Immunol 168:3771-6. 2002
    ..These outcomes suggest that genetically enhanced IDO activity inhibited T cell proliferation in vitro and in vivo. Genetic manipulation of IDO activity may be of therapeutic utility in suppressing undesirable T cell responses...
  30. ncbi Creating immune privilege: active local suppression that benefits friends, but protects foes
    Andrew L Mellor
    Immunotherapy and Cancer Centers, Medical College of Georgia, Augusta, Georgia USA
    Nat Rev Immunol 8:74-80. 2008
    ....
  31. ncbi Cutting edge: induced indoleamine 2,3 dioxygenase expression in dendritic cell subsets suppresses T cell clonal expansion
    Andrew L Mellor
    Department of Medicine, Institute of Molecular Medicine and Genetics, Medical College of Georgia, Augusta, GA 30912, USA
    J Immunol 171:1652-5. 2003
    ..Thus, IDO expression is an inducible feature of specific subsets of DCs, and provides a potential mechanistic explanation for their T cell regulatory properties...
  32. ncbi Pattern of recruitment of immunoregulatory antigen-presenting cells in malignant melanoma
    Jeffrey R Lee
    Institute of Molecular Medicine and Genetics, Augusta Veterans Affairs Medical Center, Department of Pathology, Medical College of Georgia, Augusta, Georgia, USA
    Lab Invest 83:1457-66. 2003
    ....
  33. ncbi Specific subsets of murine dendritic cells acquire potent T cell regulatory functions following CTLA4-mediated induction of indoleamine 2,3 dioxygenase
    Andrew L Mellor
    Department of Medicine, Program in Molecular Immunology, Institute of Molecular Medicine and Genetics, Medical College of Georgia, 1120, 15th Street, Augusta, GA 30912 2600, USA
    Int Immunol 16:1391-401. 2004
    ..These findings suggest that IDO-competent DCs provide a regulatory bridge, mediated by CTLA4-B7 engagement, between certain regulatory T cell subsets and naive responder T cells...
  34. ncbi Indoleamine 2,3-dioxygenase expression is restricted to fetal trophoblast giant cells during murine gestation and is maternal genome specific
    Babak Baban
    Department of Medicine, Institute of Molecular Medicine and Genetics, Medical College of Georgia 1120, 15th Street, Augusta, GA 30912 2600, USA
    J Reprod Immunol 61:67-77. 2004
    ..Hence, IDO is a key immunosuppressive mechanism in normal murine pregnancies, and it is regulated entirely through maternally inherited fetal genes...
  35. pmc Regulation of macrophage foam cell formation by alphaVbeta3 integrin: potential role in human atherosclerosis
    Alexander S Antonov
    Department of Pathology, BF 231, Medical College of Georgia, 1120 15th Street, Augusta, GA 30912, USA
    Am J Pathol 165:247-58. 2004
    ....
  36. pmc B-lymphoid cells with attributes of dendritic cells regulate T cells via indoleamine 2,3-dioxygenase
    Burles A Johnson
    Immunotherapy and Cancer Centers, Departments of Pathology and Medicine, and Flow Cytometry Core Facility, Medical College of Georgia, Augusta, GA 30912, USA
    Proc Natl Acad Sci U S A 107:10644-8. 2010
    ..Thus, IDO-competent cells constitute a distinctive B-lymphoid cell type with quintessential T-cell regulatory attributes and phenotypic features of both B cells and DCs...
  37. ncbi Indoleamine 2,3-dioxygenase, immunosuppression and pregnancy
    Andrew L Mellor
    Program in Molecular Immunology, Institute of Molecular Medicine and Genetics, Medical College of Georgia, Augusta, GA 30912, USA
    J Reprod Immunol 57:143-50. 2002
    ..Here we review evidence that cells expressing IDO contribute to immunosuppression by inhibiting T-cell responses to tumor antigens and tissue allografts, as well as fetal tissues...
  38. ncbi Policing pregnancy: Tregs help keep the peace
    Andrew L Mellor
    Program in Molecular Immunology, Institute of Molecular Medicine and Genetics, Department of Medicine, Medical College of Georgia, Augusta, GA 30912, USA
    Trends Immunol 25:563-5. 2004
  39. pmc Lentivector immunization stimulates potent CD8 T cell responses against melanoma self-antigen tyrosinase-related protein 1 and generates antitumor immunity in mice
    Yanjun Liu
    Immunology Immunotherapy Program, Medical College of Georgia Cancer Center, Medical College of Georgia, Augusta, GA 30912, USA
    J Immunol 182:5960-9. 2009
    ....
  40. ncbi Cutting edge: CpG oligonucleotides induce splenic CD19+ dendritic cells to acquire potent indoleamine 2,3-dioxygenase-dependent T cell regulatory functions via IFN Type 1 signaling
    Andrew L Mellor
    Immunotherapy Center, Medical College of Georgia, Augusta, GA 30912, USA
    J Immunol 175:5601-5. 2005
    ....
  41. pmc Immunoglobulin Fc fragment tagging allows strong activation of endogenous CD4 T cells to reshape the tumor milieu and enhance the antitumor effect of lentivector immunization
    Yuan Hong
    Immunology Immunotherapy Program, Cancer Center, Medical College of Georgia, Georgia Health Sciences University, Augusta, GA 30912, USA
    J Immunol 188:4819-27. 2012
    ....
  42. pmc Chemotherapy rescues tumor-driven aberrant CD4+ T-cell differentiation and restores an activated polyfunctional helper phenotype
    Zhi Chun Ding
    Cancer Immunotherapy Program, MCG Cancer Center, Medical College of Georgia, Augusta, GA 30912, USA
    Blood 115:2397-406. 2010
    ..We hypothesize that prevention of tumor-induced effector cell dysfunction is a major mechanism contributing to the efficacy of combined chemoimmunotherapy...
  43. pmc Depletion of endogenous tumor-associated regulatory T cells improves the efficacy of adoptive cytotoxic T-cell immunotherapy in murine acute myeloid leukemia
    Qing Zhou
    Department of Pediatrics, Division of Blood and Marrow Transplantation, Masonic Cancer Center, University of Minnesota, Twin Cities, Minneapolis, MN 55455, USA
    Blood 114:3793-802. 2009
    ....
  44. ncbi The countervailing actions of myeloid and plasmacytoid dendritic cells control autoimmune diabetes in the nonobese diabetic mouse
    Vijay Saxena
    Diabetes Research Center, Division of Endocrinology, Department of Pediatrics, Cincinnati Children s Research Foundation, University of Cincinnati, OH 45229, USA
    J Immunol 179:5041-53. 2007
    ....
  45. doi Interaction of tryptophan derivatives with SLC6A14 (ATB0,+) reveals the potential of the transporter as a drug target for cancer chemotherapy
    Senthil Karunakaran
    Department of Biochemistry and Molecular Biology, Medical College of Georgia, Augusta, GA 30912, USA
    Biochem J 414:343-55. 2008
    ..The blockade of ATB(0,+) in these cells with alpha-methyltryptophan is associated with cell cycle arrest. These studies reveal the potential of ATB(0,+) as a drug target for cancer chemotherapy...
  46. ncbi Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses
    De Yan Hou
    Immunotherapy Center and Departments of Pediatrics, Medicine, and Biostatistics, Medical College of Georgia, Augusta, Georgia
    Cancer Res 67:792-801. 2007
    ....
  47. ncbi Indoleamine 2,3-dioxygenase contributes to tumor cell evasion of T cell-mediated rejection
    Maria Friberg
    Department of Interdisciplinary Oncology, H Lee Moffitt Cancer Center, Tampa, FL 33612, USA
    Int J Cancer 101:151-5. 2002
    ..Our study provides evidence for a novel mechanism whereby tumors evade rejection by the immune system, and suggests the possibility that inhibiting IDO may be developed as an anti-cancer immunotherapeutic strategy...
  48. ncbi Dendritic cells have the option to express IDO-mediated suppression or not
    David H Munn
    Blood 105:2618. 2005
  49. ncbi Generation of cytotoxic T cells against virus-infected human brain macrophages in a murine model of HIV-1 encephalitis
    Larisa Y Poluektova
    Center for Neurovirology and Neurodegenerative Disorders, and Department of Pathology, University of Nebraska Medical Center, Omaha, NE 68198, USA
    J Immunol 168:3941-9. 2002
    ..The human PBL-NOD-SCID HIVE mouse provides a new tool for studies of cellular immune responses against HIV-1-infected brain mononuclear phagocytes during natural disease and after vaccination...
  50. pmc Inhibition of indoleamine 2,3-dioxygenase (IDO) enhances elimination of virus-infected macrophages in an animal model of HIV-1 encephalitis
    Raghava Potula
    Center for Neurovirology and Neurodegenerative Disorders, Department of Pharmacology Experimental Neurosciences, University of Nebraska Medical Center, Omaha, NE 68198 5215, USA
    Blood 106:2382-90. 2005
    ..Thus, manipulation of immunosuppressive IDO activity in HIVE may enhance the generation of HIV-1-specific CTLs, leading to elimination of HIV-1-infected macrophages in brain...
  51. pmc Indoleamine 2,3-dioxygenase is a critical regulator of acute graft-versus-host disease lethality
    Lisa K Jasperson
    University of Minnesota Cancer Center and Department of Pediatrics, Division of Bone Marrow Transplantation, Minneapolis, MN 55455, USA
    Blood 111:3257-65. 2008
    ..These studies are the first to identify a function for IDO in GVHD lethality and indicate that modulation of the IDO pathway may be an effective strategy for treatment of this disease...
  52. pmc The indoleamine 2,3-dioxygenase pathway is essential for human plasmacytoid dendritic cell-induced adaptive T regulatory cell generation
    Wei Chen
    Division of Hematology Oncology, Blood and Marrow Transplantation, Department of Pediatrics and The Cancer Center, University of Minnesota Medical School, Minneapolis, MN 55455, USA
    J Immunol 181:5396-404. 2008
    ..Our results demonstrate that the IDO pathway is essential for PDC-driven Treg generation from CD4(+)CD25(-) T cells and implicate the generation of kynurenine pathway metabolites as the critical mediator of this process...
  53. pmc Indoleamine 2,3-dioxygenase in lung dendritic cells promotes Th2 responses and allergic inflammation
    Hui Xu
    Department of Medicine, Division of Pulmonary, Allergy and Critical Care Medicine and Department of Immunology, University of Pittsburgh, Pittsburgh, PA 15213, USA
    Proc Natl Acad Sci U S A 105:6690-5. 2008
    ..Collectively, these data suggest that IDO is not required for the induction of immune tolerance in the airways but plays a role in promoting Th2-mediated allergic airway inflammation via unique effects on lung dendritic cells...
  54. pmc Toxicology and pharmacokinetics of 1-methyl-d-tryptophan: absence of toxicity due to saturating absorption
    Lee Jia
    Developmental Therapeutics Program, National Cancer Institute, Rm 8042, 6130 Executive Blvd, Bethesda, MD 20852, USA
    Food Chem Toxicol 46:203-11. 2008
    ..In conclusion, D-1MT has little toxicity when administered orally to rats and dogs. Exceeding the saturating dose of D-1MT is unlikely to cause systemic toxicity, since any further increase in D-1MT plasma levels would be minimal...
  55. ncbi Immunological concerns with bioengineering approaches
    David M Harlan
    National Institute of Diabetes, Digestive and Kidney Diseases NIH, Building 10, Room 11S210, 10 Center Drive, Bethesda, MD 20892, USA
    Ann N Y Acad Sci 961:323-30. 2002
  56. ncbi Immune response to engineered tissues and cells: breakout session summary
    David M Harlan
    National Institute of Diabetes, Digestive and Kidney Diseases NIH, Building 10, Room 11S210, 10 Center Drive, Bethesda, MD 20892, USA
    Ann N Y Acad Sci 961:350-1. 2002

Research Grants24

  1. IDO-expressing plasmacytoid dendritic cells and tumors
    David Munn; Fiscal Year: 2007
    ..This is relevant to the basic biology of tumors and to acquired peripheral tolerance, and has direct implications for clinical immunotherapy of cancer. ..
  2. IDO-expressing immunoregulatory dendritic cells
    David Munn; Fiscal Year: 2007
    ..The applicants hypothesize that IDO-mediated mechanisms may contribute to this pathologic state of acquired tolerance. ..
  3. Role of IDO malignancy
    David Munn; Fiscal Year: 2007
    ....
  4. IDO-expressing plasmacytoid dendritic cells and tumors
    David Munn; Fiscal Year: 2009
    ..This is relevant to the basic biology of tumors and to acquired peripheral tolerance, and has direct implications for clinical immunotherapy of cancer. ..
  5. IDO-expressing immunoregulatory dendritic cells
    David Munn; Fiscal Year: 2009
    ..Understanding the molecular mechanisms that link these two pathways has direct implications for the design of better clinical immunotherapy regimens in cancer. ..
  6. IDO-mediated immune regulation in established tumors
    David H Munn; Fiscal Year: 2010
    ....
  7. IDO-expressing immunoregulatory dendritic cells
    David H Munn; Fiscal Year: 2010
    ..Understanding the molecular mechanisms that link these two pathways has direct implications for the design of better clinical immunotherapy regimens in cancer. ..
  8. Role of IDO in Malignancy
    David Munn; Fiscal Year: 2006
    ..abstract_text> ..
  9. MACROPHAGE MEDIATED IMMUNOREGULATION VIA TRYPTOPHAN
    David Munn; Fiscal Year: 2002
    ..These studies will define a fundamental and previously unsuspected mechanism of T cell regulation imposed by cells of the innate immune system. ..
  10. Role of IDO malignancy
    David H Munn; Fiscal Year: 2010
    ....